Key Points {#d30e226}
==========

Acral lesions, urticarial rashes, vesicular rashes, erythematous maculopapular rashes, vascular lesions within the spectrum of livedo/purpura/necrosis, and erythema multiforme-like eruptions are the most commonly reported cutaneous symptoms of COVID-19.Dermatologists and primary care physicians should be made aware of the cutaneous symptoms linked to COVID-19 as they might be the presenting sign of infection in otherwise asymptomatic or minimally symptomatic patients.

Introduction {#Sec1}
============

In December 2019, a new infectious pathogen named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China \[[@CR1]\]. Transmitted through respiratory droplets, SARS-CoV-2 is the causative pathogen of coronavirus disease 2019 (COVID-19), which has rapidly spread across the globe to infect 188 countries. The combination of its high infectivity and lengthy asymptomatic latency period has culminated in a global pandemic affecting 18 million people and resulting in over 690,000 deaths to date \[[@CR2]\]. Although known to primarily cause interstitial pneumonia and respiratory failure, recent reports from around the world have indicated that this novel coronavirus may be associated with specific cutaneous manifestations. These dermatologic symptoms may be useful in identifying otherwise asymptomatic COVID-19 carriers, which may help slow the transmission of this highly infectious and dangerous virus. As such, an evidence-based review of peer-reviewed scientific literature was conducted to collect clinically relevant information on the cutaneous signs and symptoms of patients with COVID-19.

Materials and Methods {#Sec2}
=====================

To identify all peer-reviewed articles reporting on the cutaneous manifestations associated with COVID-19, an evidence-based review of the PubMed database was conducted on 14 May, 2020 using the search terms "Covid-19 skin," "Covid-19 rash," "Covid-19 exanthem," and "Covid-19 chilblains." Records identified through the electronic database were initially screened by title and abstract content. The full-text articles that remained were assessed for eligibility and inclusion in the evidence-based review. Peer-reviewed publications that contained original patient cases of COVID-19 and a discussion of the associated dermatologic findings were included in the analysis. Review or opinion articles that did not report on original patient cases, observational studies, or case reports that did not discuss cutaneous symptoms, and articles that were published prior to the first COVID-19 case in December 2019 were excluded.

Eligible articles were assessed for study type, location, setting, and Level of Evidence for clinical research according to the Oxford Centre for Evidence-Based Medicine 2011 guidelines \[[@CR37]\]. Study type included the following: survey snapshot studies, which reported on data collected through patient- or physician-reported surveys; case reports, which reported on the presentation and management of an individual patient; case series, which reported on the presentation of multiple patients who presented under similar circumstances; and observational prospective studies, which followed a cohort of patients over a period of time and were thus useful in collecting data on disease prevalence. Demographic characteristics such as patient sample sizes, ages, and sexes was collected. COVID-19 status and diagnostic modality were also noted. Descriptive characteristics of the cutaneous manifestations were recorded, including: rash type, location, duration, associated symptoms, relation to drug intake, and correlation to the onset of other COVID-19 symptoms.

Results {#Sec3}
=======

Study Characteristics and Patient Demographics {#Sec4}
----------------------------------------------

As depicted in Fig. [1](#Fig1){ref-type="fig"}, 115 records were initially identified in the literature search. After screening for eligibility and inclusion criteria, 34 peer-reviewed publications were ultimately included in the evidence-based review \[[@CR3]--[@CR36]\]. Study and demographic characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The majority of publications were case reports (*n* = 15), followed by case series (*n* = 13), observational prospective studies (*n* = 4), and survey-based studies (*n* = 2). All studies included were rated as Level 4 or 5 Evidence for clinical research as detailed in the Oxford Centre for Evidence-Based Medicine 2011 guidelines \[[@CR37]\]. Most studies originated from Europe (Italy, *n* = 9; Spain, *n* = 9; France, *n* = 7; Belgium, *n* = 2; joint study from Italy and Spain, *n* = 1), followed by the USA (*n* = 3), the Middle East (Qatar, *n* = 1; Iran, *n* = 1), and Southeast Asia (Thailand, *n* = 1). Patients were identified from dermatology clinics (*n* = 19) and hospitals (*n* = 15). A total of 996 patients with dermatologic symptoms were included in the analysis, of which 54.3% were female and the mean age was 37.3 years (range 1.0--98.0 years).Fig. 1Flow diagram of the search strategyTable 1Study characteristics and patient demographicsStudy IDStudy typeLevel of evidence^a^LocationSettingCOVID-19 status (diagnostic modality)Sample size^b^Age (years) and sex (M/F)Other study notesAhouach et al. \[[@CR16]\]Case report5FranceDerm clinicPositive (lab)157 F--Alramthan et al. \[[@CR11]\]Case series4QatarDerm clinicPositive (lab)227 F, 35 F--Amatore et al. \[[@CR26]\]Case report5FranceDerm clinicPositive (lab)139 M--Bouaziz et al. \[[@CR4]\]Case series4FranceDerm clinicPositive (lab)14N/A--De Masson et al. \[[@CR36]\]Case series4FranceDerm clinicPositive (lab, *n* = 25)Suspected (contact with COVID--positive case or symptomatic patient, *n* = 252)2772--98 (27 median)50% M--Diaz-Guimaraens et al. \[[@CR22]\]Case report5SpainHospitalPositive (lab)148 M--Ehsani et al. \[[@CR25]\]Case report5IranDerm clinicPositive127 M--Estebanez et al. \[[@CR7]\]Case report5SpainDerm clinicPositive128 F--Fernandez-Nieto et al. \[[@CR16]\]Case series4SpainDerm clinicPositive (clinical, *n* = 19)Suspected (contact with COVID-positive case or healthcare worker, *n* = 82)1321--56 (20 mean)53.8% M--Fernandez-Nieto et al. \[[@CR30]\]Observational prospective4SpainHospitalPositive (lab)2419--65 (45 median)75% F0% case fatalityGalvan Casas et al. \[[@CR13]\]Survey snapshot4SpainDerm clinicPositive (lab or clinical)375(49 mean)66.5% F1.9% case fatalityGenovese et al. \[[@CR28]\]Case report5ItalyDerm clinicPositive (lab)18 F--Gianotti et al. \[[@CR15]\]Case series4ItalyHospitalPositive359 F, 89 F, 57 M--Hedou et al. \[[@CR12]\]Observational prospective4FranceHomes and hospitalPositive (lab)5N/A4.9% prevalence of skin symptoms in 103 patients who were COVID-19 positive0% case fatalityHenry et al. \[[@CR6]\]Case report5FranceHospitalPositive (lab)127 F--Hunt et al. \[[@CR24]\]Case report5New YorkHospitalPositive (lab)120 M--Jimenez Cauhe et al. \[[@CR14]\]Case report5SpainHospitalPositive184 F--Joob et al. \[[@CR23]\]Case report5ThailandHospitalPositive (lab)1N/APatient was originally misdiagnosed with dengue fever48 patients were positive for COVID-19 in all of Thailand at the time of the studyKolivras et al. \[[@CR32]\]Case report5BelgiumDerm clinicPositive (lab)123 M--Landa et al. \[[@CR34]\]Case series4SpainDerm clinicPositive (lab, *n* = 3)N/A (*n* = 3)615 M, 15 F, 23 F, 24 F, 44 M, 91 M--Magro et al. \[[@CR5]\]Case series4New YorkHospitalPositive (lab)332 M, 66 F, 40 F--Mahe et al. \[[@CR21]\]Case report5FranceHospitalPositive (lab)164 F--Marzano et al. \[[@CR8]\]Case series4ItalyHospitalPositive (lab)228--83 (60 median)72.7% M13.6% case fatalityNajarian et al. \[[@CR29]\]Case report5New JerseyDerm clinicPositive (lab)158 M--Piccolo et al. \[[@CR33]\]Survey snapshot4ItalyDerm and peds clinicsPositive (lab, *n* = 4)Suspected (contact with COVID-positive case, *n* = 10)N/A (*n* = 49)6312--16 (14 median)57.4% F--Quintana-Castaneda et al. \[[@CR27]\]Case report5SpainDerm clinicPositive (lab)161 M--Recalcati \[[@CR3]\]Observational prospective4ItalyHospitalPositive (lab)18N/A20.4% prevalence of skin symptoms in 88 patients who were COVID-19 positiveRecalcati et al. \[[@CR9]\]Observational prospective4ItalyDerm clinicNegative (lab, antibody testing not performed)1413--39 (17.5 mean)57.1% F11 patients were childrenSachdeva et al. \[[@CR31]\]Case series4ItalyHospitalPositive (lab)371 F, 77 F, 72 F--Tammaro et al. \[[@CR10]\]Case series4Italy, SpainHospitalPositive3N/A--Torres-Navarro et al. \[[@CR35]\]Case series4SpainDerm clinicNegative (lab, antibody testing not performed)216 F, 16 M--Tosti et al. \[[@CR20]\]Case series4ItalyDerm clinicNot tested426 M, 16 F, 18 F, 48 MPatients not tested because of limited testing capacity but all presented during the COVID-19 outbreakVan Damme et al. \[[@CR17]\]Case series4BelgiumDerm clinicPositive (lab, *n* = 1; clinical, *n* = 1)271 M, 39 F1 patient died 2 weeks after presentationZengarini et al. \[[@CR19]\]Case report5ItalyHospitalPositive (lab)167 F--*COVID-19* coronavirus disease 2019, *Derm* dermatologic, *F* female, *ID* identification, *lab* laboratory, *M* male, *N/A* not available, *peds* pediatric^a^Level of Evidence for clinical research as detailed in the Oxford Centre for Evidence-Based Medicine 2011 guidelines \[[@CR37]\]^b^Sample size denotes the number of Derm patients discussed in the study

The majority of patients (58.2%) had a laboratory-confirmed diagnosis of COVID-19. Exceptions include De Masson et al. (252 out of 277 patients were suspected to have COVID-19 because of extracutaneous symptoms and/or prior contact with a patient with COVID-19), Fernandez-Nieto et al. (82 out of 132 patients were suspected to have COVID-19 because of prior contact with a patient or healthcare worker with COVID-19), Landa et al. (three out of six patients were not tested for COVID-19), Piccolo et al. (59 out of 63 patients were either not tested or had missing information on COVID-19 status), Recalcati et al. (14 out of 14 patients were COVID-19 negative on a polymerase chain reaction \[PCR\] analysis), Torres-Navarro et al. (two out of two patients were COVID-19 negative on PCR analysis), and Tosti et al. (four out of four patients were not tested for COVID-19) \[[@CR9], [@CR18], [@CR20], [@CR33]--[@CR36]\]. These non-laboratory confirmed patients all presented during the COVID-19 outbreak and, for those with a negative COVID-19 PCR result, antibody testing was not available to establish the possibility of prior infection. The case fatality rate range was 0.0--13.6% \[[@CR8], [@CR13], [@CR30]\]. For studies that examined a larger cohort of patients who were COVID-19 positive (both with cutaneous and extracutaneous symptoms), the prevalence range of skin symptoms was 4.9--20.4% \[[@CR3]--[@CR12]\].

Characteristics of Cutaneous Symptoms {#Sec5}
-------------------------------------

Table [2](#Tab2){ref-type="table"} summarizes the characteristics of the cutaneous symptoms described in the COVID-19 literature. These dermatologic manifestations were then grouped together into categories using common descriptive terminology and photographic evidence. These categories included: erythema multiforme-like eruptions, erythematous maculopapular rashes, erythematous rashes not otherwise specified, figurate erythema, vascular rashes within the spectrum of livedo/purpura/necrosis, pityriasis rosea-like eruptions, acral lesions resembling pseudo-chilblains, symmetrical drug-related intertriginous and flexural exanthema, urticarial rashes, vesicular rashes, and other rashes.Table 2Characteristics of cutaneous symptoms of coronavirus disease 2019 (COVID-19)Study IDRash type, *n*Rash location, *n*Rash durationAssociated cutaneous symptoms, *n*Relation to new drug intakeRelation to onset of other COVID-19 symptoms, *n*Other rash notesAhouach et al. \[[@CR16]\]Maculopapular (1)Trunk and limbs9 daysBurningNo new drug intakeBeforePerivascular lymphocytic infiltrate on skin biopsyAlramthan et al. \[[@CR11]\]Acral (2)Dorsal fingers (1)Subungual region (1)----No new drug intakeBefore (2)--Amatore et al. \[[@CR26]\]Figurate erythema (1)Arms (including palms), neck, chest, and abdomen7 days--No new drug intakeAt onsetPerivascular lymphocytic infiltrate on skin biopsyBouaziz et al. \[[@CR4]\]Erythema-NOS (4)Maculopapular (1)Urticaria (1)Vesicular (2)Vascular (3)Acral (2)Other (1)TrunkLimbsFeet------After (14)Other rash was an eruptive cherry angiomaAcral lesions were also seen in close contacts of patients (*n* = 40, contacts did not have confirmatory testing for COVID-19)De Masson et al. \[[@CR36]\]Maculopapular (25)Urticaria (26)Vesicular (41)Vascular (11)Acral (142)Other (41)Trunk and limbs (103)Face (12)Limbs (2)Hands/feet (56)--------Other rashes included eczematous, angiomatous, and annular lesionsNo relation to cold exposure or comorbiditiesPerivascular mononuclear infiltrate with vascular microthrombi on skin biopsyDiaz-Guimaraens et al. \[[@CR22]\]Maculopapular (1)Buttocks and legs5 daysPruritisNo new drug intakeAfterPerivascular lymphocytic infiltrate on skin biopsyEhsani et al. \[[@CR25]\]Pityriasis rosea (1)Trunk and arms--PruritisNo new drug intakeAfter--Estebanez et al. \[[@CR7]\]Urticaria (1)Heels--PruritisNo new drug intakeAfter--Fernandez-Nieto et al. \[[@CR16]\]Acral (95)Erythema multiforme (37)Digits (Acral)Hands and feet (erythema multiforme)9 days--No new drug intakeAt onset (3)After (16)Statistically, acral lesions were associated with a greater patient age and erythema multiforme was associated with more ventrally distributed lesionsFernandez-Nieto et al. \[[@CR30]\]Vesicular (24)Head (4)Chest (21)Trunk (14)Arms (8)Legs (10)Palms/soles (2)10 daysPruritis (20)7 patients had prior drug intakeBefore (2)At onset (3)After (19)75% of patients had a diffuse polymorphic rash at various stages of evolution, 25% had a localized monomorphic rash at the same stage of evolution4 patients' lesions were tested and were negative for COVID-19 PCRGalvan Casas et al. \[[@CR13]\]Acral (71)Vesicular (34)Urticaria (73)Maculopapular (176)Vascular (21)Hands and feet (Acral)Trunk or limbs (Vesicular)Trunk or palms (Urticaria)Limbs (Maculopapular)Trunk or digits (Vascular)6--13 daysPruritis (213)Pain (32)Burning (22)Many patients had prior drug intake (unable to ascertain exact number)Before (22)At onset (212)After (139)More HSV reactivation noted in cohortSome maculopapular rashes were described as resembling pityriasis rosea or erythema multiformeStatistically, vascular lesions were associated with the greatest patient age and the worst outcomes, followed by maculopapular rashes, urticaria, vesicular rashes, and finally acral lesionsGenovese et al. \[[@CR28]\]Vesicular (1)Trunk7 days--No new drug intakeAfter--Gianotti et al. \[[@CR15]\]Maculopapular (3)Trunk (3)Arms (2)Legs (1)5--10 daysPruritis (1)--Before (1)After (2)Superficial perivascular dermatitis with small-vessel thrombosis on skin biopsyHedou et al. \[[@CR12]\]Erythema-NOS (2)Urticaria (2)Other (1)Face and arms (3)2--6 daysPruritis (5)--Before (1)At onset (4)Other rash was a reactivation of HSV-1Henry et al. \[[@CR6]\]Maculopapular (1)Forehead, hand, and foot--PruritisNo new drug intakeBefore--Hunt et al. \[[@CR24]\]Maculopapular (1)Trunk and limbs------At onset--Jimenez Cauhe et al. \[[@CR14]\]Vascular (1)Axilla--Mild pruritisHad prior drug intakeAfter--Joob et al. \[[@CR23]\]Vascular (1)--------Before--Kolivras et al. \[[@CR32]\]Acral (1)Feet and toes--PainNo new drug intakeAfterNo relation to cold exposure or comorbiditiesPerivascular lymphocytic infiltrate on skin biopsyLanda et al. \[[@CR34]\]Acral (6)Toes (5)Soles (1)--Mild pruritis (2)Mild pain (3)--Before (1)After (5)No relation to cold exposure or comorbiditiesMagro et al. \[[@CR5]\]Vascular (3)Buttocks (1)Chest, arms, and legs (1)Palms and soles (1)----2 patients had prior drug intakeAfter (3)Thrombogenic vasculopathy with deposition of C4d and C5b-9 on skin biopsyMahe et al. \[[@CR21]\]SDRIFE (1)Trunk and arms5 days--Had prior drug intakeAfterThe rash both appeared and disappeared while taking new oral drugMarzano et al. \[[@CR8]\]Vascular (22)Trunk (22)Limbs (4)4--15 daysMild pruritis (9)No new drug intakeBefore (1)At onset (2)After (16)7 patients' skin biopsies showed viral infection6 patients had a diffuse exanthemNajarian et al. \[[@CR29]\]Maculopapular (1)Limbs, shoulders, trunk, chest, and abdomen4 daysPruritisHad prior drug intakeAfterPatient was taking azithromycin when rash developed but had previously taken it without complicationsPiccolo et al. \[[@CR33]\]Acral (63)Hands/feet (63)--Pruritis (30)Pain (30)--AfterNo relation to cold exposure or comorbiditiesTwo different patterns of lesions were observed: erythematous-edematous and blistering typesQuintana-Castaneda et al. \[[@CR27]\]Urticaria (1)Limbs7 daysMild pruritisNo new drug intakeBefore--Recalcati \[[@CR3]\]Erythema-NOS (14)Urticaria (3)Vesicular (1)Trunk"A few days"Minimal pruritisNo new drug intakeAt onset (8)After (10)--Recalcati et al. \[[@CR9]\]Acral (14)Feet (10)Hands (6)14--28 daysMinimal pruritisNo new drug intakeBefore (11)After (3)No relation to cold exposure or comorbiditiesSachdeva et al. \[[@CR31]\]Maculopapular (2)Vesicular (1)Trunk (3)Legs (2)Chest (1)10 daysPruritis (2)1 patient had prior drug intakeAt onset (1)After (2)One of the rashes resembled Grover's diseaseTammaro et al. \[[@CR10]\]Vesicular (3)Trunk (3)--Mild pruritis (3)--After (3)Rash appeared to belong to Herpesviridae familyTorres-Navarro et al. \[[@CR35]\]Acral (2)Fingers----------Tosti et al. \[[@CR20]\]Acral (4)Heels (2)Toes (2)--Pain (2)Burning (1)Pruritis (1)1 patient had prior drug intakeBefore (2)After (2)No relation to cold exposure or comorbiditiesVan Damme et al. \[[@CR17]\]Urticaria (2)Trunk and legs (2)--Pruritis (1)No new drug intakeAt onset--Zengarini et al. \[[@CR19]\]Erythema-NOS (1)Neck and trunk7 daysMild pruritisHad prior drug intakeAfterPerivascular lymphocytic infiltrate on skin biopsy*HSV* herpes simplex virus, *ID* identification, *NOS* not otherwise specified, *PCR* polymerase chain reaction, *SDRIFE* symmetrical drug-related intertriginous and flexural exanthema

As seen in Table [3](#Tab3){ref-type="table"}, acral lesions were the most common category identified (40.4% of all cases), followed by erythematous maculopapular rashes (21.3%), vesicular rashes (13.0%), urticarial rashes (10.9%), other rashes (4.3%, including one eruptive cherry angioma, one reactivation of herpes simplex virus-1, and 41 unspecified cases of eczematous, angiomatous, or annular lesions), vascular rashes within the spectrum of livedo/purpura/necrosis (4%), erythema multiforme-like eruptions (3.7%), and unspecified erythematous rashes (2.1%). Cutaneous manifestations resembling symmetrical drug-related intertriginous and flexural exanthema, pityriasis rosea, and figurate erythema were the least common (0.3% combined).Table 3Summary of rashes by type, patient characteristics, and onset characteristicsRash typeSample size, *n* (%)Age, mean years^a^Female^a^, *n* (%)Relation to onset of other COVID-19 symptoms^b^Before (%)At onset (%)After (%)Acral lesions402 (40.4)23.2211 (54.1)21 (21.0)24 (24.0)55 (55.0)Erythematous maculopapular rashes212 (21.3)53.2115 (55.6)11 (5.9)110 (58.8)66 (35.3)Vesicular rashes129 (13.0)48.361 (50.8)8 (9.5)24 (28.6)52 (61.9)Urticarial rashes109 (10.9)38.359 (59.0)5 (6.4)46 (59.0)27 (34.6)Other rashes^c^43 (4.3)45.625 (69.4)0 (0)1 (50.0)1 (50.0)Vascular rashes40 (4.0)77.516 (47.1)2 (6.9)18 (62.1)9 (31.0)Erythema multiforme-like eruptions37 (3.7)12.215 (40.5)------Erythematous rash (not otherwise specified)21 (2.1)671 (100)0 (0)2 (28.6)5 (71.4)Symmetrical drug-related intertriginous and flexural exanthema1 (0.1)641 (100)0 (0)0 (0)1 (100)Pityriasis rosea1 (0.1)270 (0)0 (0)0 (0)1 (100)Figurate erythema1 (0.1)390 (0)0 (0)1 (100)0 (0)Total 996 (100)Mean 37.3Total 504 (54.3)Total 47 (9.6)Total 226 (46.1)Total 217 (44.3)*COVID-19* coronavirus disease 2019^a^Studies by Bouaziz et al., Hedou et al., Joob and Wiwanikit, Recalcati et al., and Tammaro et al. excluded because of inability to extract exact data \[[@CR3], [@CR4], [@CR10], [@CR12], [@CR23]\]^b^Studies by De Masson et al., Fernandez-Nieto et al., Piccolo et al., Recalcati et al., and Torres-Navarro et al. excluded because of inability to extract exact data \[[@CR3], [@CR16], [@CR33], [@CR35], [@CR36]\]^c^Other rashes included: eruptive cherry angioma (*n* = 1), reactivation of herpes simplex virus-1 (*n* = 1), and unspecified cases of eczematous, angiomatous, or annular lesions (*n* = 41)

Mean patient age associated with each dermatologic category was as follows: vascular rashes resembling livedo/purpura/necrosis (77.5 years), unspecified erythematous rashes (67.0 years), erythematous maculopapular rashes (53.2 years), vesicular rashes (48.3 years), other rashes (45.6 years), urticarial rashes (38.3 years), acral lesions (23.2 years), and erythema multiforme-like eruptions (12.2 years). All rashes had a female predominance except for vascular rashes (52.9% male predominance), erythema multiforme-like eruptions (59.5% male predominance), pityriasis rosea (only one case reported and the patient was male), and figurate erythema (only one case reported and the patient was male).

Although not all studies reported on the mean duration of these cutaneous manifestations, most studies described signs and symptoms that resolved within 2--15 days. One study reported persistent acral lesions that required 2--4 weeks for complete resolution \[[@CR9]\]. Of the dermatologic findings that were symptomatic, the majority were pruritic (*n* = 295), followed by painful (*n* = 68) or burning (*n* = 24). Most patients had no new drug intake in the 2 weeks preceding the rash onset. Some studies went into more descriptive detail to characterize the skin findings. Fernandez-Nieto et al. observed two different types of vesicular rashes: a diffuse polymorphic rash at various stages of evolution (observed in 75% of patients) and a localized monomorphic rash at the same stage of evolution (observed in 25% of patients) \[[@CR30]\]. The single case of a vesicular rash reported by Sachdeva et al. was described as resembling Grover's disease \[[@CR31]\]. Piccolo et al. observed two different lesion patterns for acral lesions: erythematous-edematous types and blistering types. A few articles also described skin biopsy findings, which almost uniformly revealed a perivascular mononuclear/lymphocytic infiltrate with occasional small-vessel thrombosis \[[@CR8], [@CR15], [@CR16], [@CR19], [@CR22], [@CR26], [@CR32], [@CR36]\]. One study in particular revealed a complement-mediated thrombogenic vasculopathy with deposition of C4d and C5b-9 on histopathology \[[@CR5]\].

The association and time relationship between each dermatologic manifestation and the non-cutaneous symptoms of COVID-19 (such as fever, cough, shortness of breath, malaise, and myalgia) are depicted in Table [3](#Tab3){ref-type="table"}. The appearance of nearly half of the cutaneous findings coincided with the onset of other COVID-19 symptoms (46.1% of all cases). Other rashes appeared shortly after (44.3%) or before (9.6%) the onset of non-cutaneous COVID-19 manifestations. Erythematous maculopapular rashes were more likely to present concurrently with other symptoms (58.8%) compared with before (5.9%) or after (35.3%). Urticarial rashes also frequently coincided with the onset of non-cutaneous symptoms (59.0%) compared with before (6.4%) or after (34.6%). The same trend was observed for vascular rashes, with the majority of cases appearing alongside other COVID-19 symptoms (62.1%) compared with before (6.9%) or after (31.0%). Of the cases reported, otherwise unspecified erythematous rashes presented most frequently after other symptoms of COVID-19 (71.4%) rather than before (0%) or at the same time (28.6%). Acral lesions also more commonly appeared after (55.0%) compared with before (21.0%) or at the same time (24.0%) as extracutaneous symptoms. Vesicular rashes were also more likely to present after other symptoms (61.9%) compared with before (9.5%) or at the same time (28.6%).

A breakdown of COVID-19 skin symptoms by location is depicted in Table [4](#Tab4){ref-type="table"}. Hands and feet were the most frequently reported site for dermatologic findings (55.1% of cases), followed by a mixed location pattern (26.8%), trunk alone (10.2%), limbs alone (3.3%), face and neck (3.0%), palms and soles (1.2%), and chest and abdomen (0.4%).Table 4Summary of rashes by locationRash locationSample size^a^, *n* (%)Face/neck15 (3.0)Chest/abdomen2 (0.4)Trunk/back52 (10.2)Arms/legs17 (3.3)Hands/feet280 (55.1)Palms/soles6 (1.2)Mixed^b^136 (26.8)Total*508 (100)*^a^Studies by Bouaziz et al. and Galvan Casas excluded because of inability to extract exact data \[[@CR4], [@CR13]\]^b^Most common mixed pattern was trunk and limbs

Discussion {#Sec6}
==========

The repercussions of the SARS-CoV-2 pandemic is substantial, impacting millions of patients medically, financially, and socially. Unfortunately, this highly virulent pathogen is extremely difficulty to contain given its prolonged asymptomatic latency period and respiratory droplet transmission pattern. Cutaneous manifestations of COVID-19 may help assist in the identification of carriers, enabling healthcare officials to implement appropriate measures to stem the spread and, if appropriate, provide earlier COVID-19-specific care to these individuals.

Reports of the dermatologic signs and symptoms associated with COVID-19 are mounting in the literature, but these studies have yet to be comprehensively evaluated. This article presents an extensive evidence-based review of the COVID-19 scientific literature to identify and present the cutaneous manifestations of SARS-CoV-2. Thirty-four studies on 996 patients with dermatologic conditions from eight different countries and four different continents were included in this report.

The most commonly reported dermatologic findings included acral lesions resembling pseudo-chilblains, erythematous maculopapular rashes, vesicular rashes, urticarial rashes, other rashes including eruptive cherry angioma and herpes simplex virus-1 reactivation, vascular rashes within the spectrum of livedo/purpura/necrosis, erythema multiforme-like eruptions, and otherwise unspecified erythematous rashes. Most of these rashes may be attributable to a COVID-19-specific viral exanthem; however, some dermatologic manifestations may be by-products of the thrombogenic and immune deregulatory effects of SARS-CoV-2, as evidenced by the cutaneous reaction patterns and histopathological findings \[[@CR38]\].

Acral lesions, also described as pseud-chilblains or pernio-like lesions in the literature, were the most common type of rash presented in the literature, primarily affecting young adult patients and presenting after the onset of non-cutaneous COVID-19 symptoms \[[@CR40]\]. According to Galvan Casas et al., acral lesions were significantly associated with younger aged patients and with a milder disease course. Patients with acral lesions typically required fewer treatments than those with vascular rashes, erythematous maculopapular rashes, urticarial rashes, and vesicular rashes \[[@CR13]\]. Of note, these acral lesions were largely unrelated to cold exposure (secondary to social isolation and stay-at-home orders) or a prior history of Raynaud's disease \[[@CR9], [@CR20], [@CR32]--[@CR34], [@CR36]\]. Moreover, many of the patients who presented with acral lesions did not have a laboratory-confirmed diagnosis of COVID-19 and were instead suspected of having the disease because they had known infected contacts. As previously reported, many children presenting with acral lesions during the COVID-19 pandemic actually had laboratory-negative SARS-CoV-2 PCR \[[@CR41]\]. This could in part be explained by the rapid decrease in viral loads after initial symptomatology, particularly in children who were not tested immediately because of country-wide lockdown measures. As such, although these cutaneous findings are likely COVID-19-induced acral lesions rather than primary pernio disease, their association with SARS-CoV-2 is not irrefutable. The majority of acral lesion cases were associated with milder disease, resolving disease, or negative laboratory testing. In one study, acral lesions were found in many close patient contacts \[[@CR4]\]. As this rash affected a large number of patients, it may be useful for detecting individuals more likely to unknowingly transmit the disease. As such, acral lesions may be most appropriate for epidemiologic uses rather than diagnostic applications.

Erythematous maculopapular rashes were the second most common skin manifestation, affecting mostly middle-aged patients and presenting at the same time as other symptoms. Vesicular rashes and urticarial rashes were the next most frequent dermatologic findings. Both rash types affected adults, but vesicular rashes typically presented after the onset of extracutaneous COVID-19 manifestations while urticarial rashes occurred simultaneously. Urticarial rashes and erythematous maculopapular rashes are often drug induced, which lessens the ability of these cutaneous reactions to serve as a COVID-19 diagnostic marker. Vesicular lesions, however, tend to be more specific to viral exanthemas. As such, vesicular lesions may be a more useful COVID-19 diagnostic tool. Unfortunately, the pattern of vesicular lesions varies amongst COVID-19 studies, from diffuse polymorphic to localized monomorphic distributions. Further studies evaluating the type of vesicular rash most strongly associated with COVID-19 are warranted prior to determining the diagnostic utility of this particular cutaneous lesion.

Vascular rashes belonging to the spectrum of livedo/purpura/necrosis, while relatively uncommon, were primarily seen in elderly patients at the onset of non-dermatologic COVID-19 symptoms. According to Galvan Casas et al., vascular rashes were significantly correlated with more advanced age and/or severe symptomatology. Unsurprisingly, these vascular rashes were then associated with higher rates of hospital admission and mechanical ventilation compared with erythematous maculopapular rashes, urticarial rashes, vesicular rashes, and acral lesions \[[@CR13]\]. Given their correlation to disease severity, these vascular rashes might represent a COVID-19-specific complication in which the virus-induced pro-thrombotic state provokes vascular occlusion and ischemia \[[@CR38]\]. Consequently, these rashes may be a useful prognostic marker that can help guide medical management.

Erythema multiforme-like eruptions were infrequent and typically occurred in young patients, particularly children. Other rashes (including one herpes simplex virus-1 reactivation and one eruptive cherry angioma), erythema multiforme-like eruptions, pityriasis rosea, and symmetrical drug-related intertriginous and flexural exanthema were also rarely observed. As such, these cutaneous manifestations may not be directly correlated to the COVID-19 virus. However, the true incidence of erythema multiforme-like eruptions and pityriasis rosea may be under-reported, as some studies grouped many unspecified rashes of annular or angiomatous appearance into the other rash category \[[@CR36]\]. The frequency of pityriasis rosea in particular warrants further investigation, as this rash has previously been linked to other viruses \[[@CR39]\].

As with any cutaneous eruption, one must consider that it may have been triggered by a medication. Drugs used to treat COVID-19, such as antimalarials, azithromycin, remdesivir, antiretrovirals, corticosteroids, and biologics, are known to cause acute urticaria, vasculitis, and other pruritic lesions. The rashes included in this evidence-based review that coincided with a recent medication intake were determined to be non-drug induced, as most authors reported that, for each questionable patient, the administered drug had either previously been taken without complication or was not known to cause the specific rashes observed. Of note, some patients with COVID-19 with previous skin conditions such as rosacea, acne, eczema, and atopic dermatitis experienced a flare during the course of their disease \[[@CR42]\].

Finally, the case fatality rate reported by the studies included in this analysis had a range of 0.0--13.6%. This span encompasses the most recent and accurate estimation of the overall COVID-19 mortality rate of 3.8% \[[@CR2]\]. As a rapidly evolving situation, COVID-19 peer-reviewed reports are rarely in the form of high-powered, strictly controlled clinical trials. As such, one of the limitations of this study was the inability to collect complete and standardized data sets to allow for in-depth comparisons between rash subgroups. Given the novelty of COVID-19 and the scientific literature's still limited understanding of the symptomatology of this disease, another limitation is the distinct possibility that many of the articles included in this review do not reflect the entire spectrum and variability of cutaneous lesions of COVID-19. This can only be improved upon with continued observation and detailed reporting. Additionally, not all studies included in this analysis reported on patients with a laboratory-confirmed diagnosis of COVID-19; however, this may also be attributable to the unprecedented turmoil induced by this novel coronavirus, as testing is often limited or inaccessible.

Conclusions {#Sec7}
===========

A study of 552 hospitals in mainland China initially indicated a 0.2% prevalence of COVID-19 skin symptoms \[[@CR43]\]. However, the prevalence suggested by this evidence-based analysis implies that the true rate is much greater, affecting up to 20.4% of patients with COVID-19. As a potential correlate to disease severity, prognosis, or infectibility, it is critical that all healthcare professionals be well versed in these increasingly common cutaneous manifestations of COVID-19. Hand surgeons and podiatrists must be even more aware of these lesions, as they most often appear on the hands and feet. Additional standardized studies of the COVID-19 rashes are warranted to further establish the diagnostic validity and utility of these visible findings.
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